Bionano Announces Publication Shows That OGM Can Resolve Translocation Partners Involving MYC In Multiple Myeloma More Effectively Than Current Methods
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics announced a publication showing that their Optical Genome Mapping (OGM) technology can more effectively resolve MYC gene translocations in multiple myeloma than current methods. This suggests potential for broader adoption of OGM in blood cancer diagnostics.
October 24, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano Genomics' OGM technology has been shown to effectively resolve MYC gene translocations in multiple myeloma, suggesting potential for broader adoption in blood cancer diagnostics.
The publication highlights the effectiveness of Bionano's OGM technology in resolving MYC gene translocations, a key biomarker in multiple myeloma. This could lead to increased adoption of OGM in blood cancer diagnostics, potentially boosting Bionano's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100